Neuroendocrine gastro-enteropancreatic tumors – from eminence based to evidence-based medicine – A Scandinavian view

References

• IMModlin, KOberg, DCChung, RTJensen, WWde Herder, RVThakker, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72.
   PubMed Web of Science ®Google Scholar
• JCYao, MHassan, APhan, CDagohoy, CLeary, JEMares, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.
   PubMed Web of Science ®Google Scholar
• FTBosman, FCarneiro. WHO Classification of Tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010.
   Google Scholar
• ASundin, MPVullierme, GKaltsas, UPlockinger. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90:167–83.
   PubMed Web of Science ®Google Scholar
• MPerri, PErba, DVolterrani, ELazzeri, GBoni, MGrosso, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323–33.
   PubMed Web of Science ®Google Scholar
• YKrausz, NFreedman, RRubinstein, ELavie, MOrevi, STshori, et al. Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111) In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol 2011;13:583–93.
   PubMed Web of Science ®Google Scholar
• MGabriel, CDecristoforo, DKendler, GDobrozemsky, DHeute, CUprimny, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.
   PubMed Web of Science ®Google Scholar
• HOrlefors, ASundin, UGarske, CJuhlin, KOberg, BSkogseid, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–400.
   PubMed Web of Science ®Google Scholar
• KPKoopmans, OCNeels, IPKema, PHElsinga, WJSluiter, KVanghillewe, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489–95.
   PubMed Web of Science ®Google Scholar
• TBinderup, UKnigge, ALoft, BFederspiel, AKjaer. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978–85.
   PubMed Web of Science ®Google Scholar
• LTaupenot, KLHarper, DTO’Connor. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134–49.
   PubMed Web of Science ®Google Scholar
• IMModlin, BIGustafsson, SFMoss, MPavel, AVTsolakis, MKidd. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427–43.
   PubMed Web of Science ®Google Scholar
• SWelin, MStridsberg, JCunningham, DGranberg, BSkogseid, KOberg, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89:302–7.
   PubMed Web of Science ®Google Scholar
• WWde Herder. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:33–41.
   PubMed Web of Science ®Google Scholar
• AScarpa, WMantovani, PCapelli, SBeghelli, LBoninsegna, RBettini, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824–33.
   PubMed Web of Science ®Google Scholar
• OHentic, ACouvelard, VRebours, MZappa, SDokmak, PHammel, et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 2011;18:51–9.
   PubMed Web of Science ®Google Scholar
• RKianmanesh, DO’Toole, ASauvanet, PRuszniewski, JBelghiti. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases. J Chir 2005;142:208–19.
   PubMedGoogle Scholar
• JEriksson, PStalberg, ANilsson, JKrause, CLundberg, BSkogseid, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008;32:930–8.
   PubMed Web of Science ®Google Scholar
• PRuszniewski, PRougier, ARoche, PLegmann, ASibert, SHochlaf, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624–30.
   PubMed Web of Science ®Google Scholar
• TJVogl, TGruber, NNNaguib, RHammerstingl, NENour-Eldin. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. Ajr 2009;193:941–7.
   PubMed Web of Science ®Google Scholar
• DJKwekkeboom, JMueller-Brand, GPaganelli, LBAnthony, SPauwels, LKKvols, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S–6S.
   PubMed Web of Science ®Google Scholar
• IMModlin, MPavel, MKidd, BIGustafsson. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88.
   PubMed Web of Science ®Google Scholar
• KOberg. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92–7.
   PubMed Web of Science ®Google Scholar
• SEkeblad, ASundin, ETJanson, SWelin, DGranberg, HKindmark, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986–91.
   PubMed Web of Science ®Google Scholar
• NCTurner, SJStrauss, DSarker, RGillmore, AKirkwood, AHackshaw, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102:1106–12.
   PubMed Web of Science ®Google Scholar
• JCYao, MHShah, TIto, CLBohas, EMWolin, EVan Cutsem, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
   PubMed Web of Science ®Google Scholar
• ERaymond, LDahan, JLRaoul, YJBang, IBorbath, CLombard-Bohas, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.
   PubMed Web of Science ®Google Scholar
• ARinke, HHMuller, CSchade-Brittinger, KJKlose, PBarth, MWied, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.
   PubMed Web of Science ®Google Scholar
• MECaplin, MPavel, JBCwikla, ATPhan, MRaderer, ESedlackova, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224–33.
   PubMed Web of Science ®Google Scholar
• RSYalow, SABerson. Immunoassay of endogenous plasma insulin in man 1960. Obesity Res 1996;4:583–600.
   PubMedGoogle Scholar
• KOberg. Peptide hormone markers in endocrine gastrointestinal tumorsI. Acta Univers Upsal 1981;30:383.
   Google Scholar
• KOberg, LGrimelius, GLundqvist, LELorelius. Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. Acta Med Scand 1981;210:145–52.
   PubMed Web of Science ®Google Scholar
• KOberg, LWide, HBostrom. HCG-alpha and HCG-beta subunits as tumour markers during therapy in a case with so-called "non-functioning" islet cell tumour. Acta Med Scand 1981;210:231–3.
   PubMed Web of Science ®Google Scholar
• KOberg, OWalinder, HBostrom, GLundqvist, LWide. Peptide hormone markers in screening for endocrine tumors in multiple endocrine adenomatosis type I. Am J Med 1982;73:619–30.
   PubMed Web of Science ®Google Scholar
• LWide. Radioimmunoassays employing immunosorbents. Acta Endocrinol Suppl 1969;142:207–21.
   PubMedGoogle Scholar
• KOberg, GLundqvist. Meal-stimulated and atropine-inhibited secretion of pancreatic polypeptide in healthy subjects, members of MEA I families and patients with malignant endocrine tumours of the gastrointestinal tract. Regul Pept 1983;5:273–82.
   PubMed Web of Science ®Google Scholar
• ETheodorsson-Norheim, KOberg, SRosell, HBostrom. Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut. Gastroenterology 1983;85:881–9.
   PubMed Web of Science ®Google Scholar
• INorheim, ETheodorsson-Norheim, EBrodin, KOberg, GLundqvist, SRosell. Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors. Regul Pept 1984;9:245–57.
   PubMed Web of Science ®Google Scholar
• INorheim, EWilander, KOberg, ETheodorsson-Norheim, MLLundqvist, PLindgren, et al. Tachykinin production by carcinoid tumours in culture. Eur J Cancer Clin Oncol 1987;23:689–95.
   PubMedGoogle Scholar
• INorheim, ETheodorsson-Norheim, EBrodin, KOberg. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605–12.
   PubMed Web of Science ®Google Scholar
• KOberg, GLundqvist, LWide. Treatment of the carcinoid syndrome with SMS 201-995;a somatostatin analogue. Scand J Gastroenterol 1986;119:191–2.
   Web of Science ®Google Scholar
• KOberg, ETheodorsson-Norheim, INorheim. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 1987;22:1041–8.
   PubMed Web of Science ®Google Scholar
• BEriksson, HArnberg, KOberg, UHellman, GLundqvist, CWernstedt, et al. A polyclonal antiserum against chromogranin A and B–a new sensitive marker for neuroendocrine tumours. Acta Endocrinol 1990;122:145–55.
   PubMedGoogle Scholar
• DTO’Connor, LJDeftos. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145–51.
   PubMed Web of Science ®Google Scholar
• BEriksson, HArnberg, KOberg, UHellman, GLundqvist, CWernstedt, et al. Chromogranins–new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325–9.
   PubMed Web of Science ®Google Scholar
• HBlaschko, RSComline, FHSchneider, MSilver, ADSmith. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 1967;215:58–9.
   PubMed Web of Science ®Google Scholar
• MStridsberg, UHellman, EWilander, GLundqvist, KHellsing, KOberg. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139:329–37.
   PubMed Web of Science ®Google Scholar
• LLarsson, JAlumets, BEriksson, RHåkansson, GLunqvist, KÖberg, et al. Antiserum directed against both chromogranin A and B (CAB) is a general marker for peptide hormone producing endocrine cells and toumors. Endoc Pathol 1992;3:14–22.
   Web of Science ®Google Scholar
• LLundin, INorheim, JLandelius, KOberg, ETheodorsson-Norheim. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264–9.
   PubMed Web of Science ®Google Scholar
• AThorson, GBiorck, GBjorkman, JWaldenstrom. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47:795–817.
   PubMed Web of Science ®Google Scholar
• KFuna, VPapanicolaou, CJuhlin, JRastad, GAkerstrom, CHHeldin, et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990;50:748–53.
   PubMed Web of Science ®Google Scholar
• JWaltenberger, LLundin, KOberg, EWilander, KMiyazono, CHHeldin, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993;142:71–8.
   PubMed Web of Science ®Google Scholar
• AChaudhry, KOberg, EWilander. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13:27–35.
   PubMed Web of Science ®Google Scholar
• TCui, AVTsolakis, SCLi, JLCunningham, TLind, KOberg, et al. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. Eur J Endocrinol 2013;168:253–61.
   PubMed Web of Science ®Google Scholar
• SCLi, AEssaghir, CMartijn, RVLloyd, JBDemoulin, KOberg, et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol 2013;26:685–96.
   PubMed Web of Science ®Google Scholar
• AHemmingsson, PGLindgren, LELorelius, KOberg. Diagnosis of endocrine gastrointestinal tumours. Acta Radiol Diagn 1981;22:657–62.
   PubMedGoogle Scholar
• TAndersson, BEriksson, AHemmingsson, PGLindgren, KOberg. Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours. Acta Radiol 1987;28:535–9.
   PubMed Web of Science ®Google Scholar
• TAndersson, BEriksson, PGLindgren, EWilander, KOberg. Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors. Ann Sur 1987;206:728–32.
   PubMed Web of Science ®Google Scholar
• BEriksson, MBergstrom, ALilja, HAhlstrom, BLangstrom, KOberg. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol (Madr) 1993;32:189–96.
   PubMed Web of Science ®Google Scholar
• JEWestlin, ETJanson, HArnberg, HAhlstrom, KOberg, SNilsson. Somatostatin receptor scintigraphy of carcinoid tumours using the 111In-DTPA-D-Phe1]-octreotide. Acta Oncol (Madr) 1993;32:783–6.
   PubMed Web of Science ®Google Scholar
• JEWestlin, HAhlstrom, JYla-Jaaski, KOberg, SNilsson. Three-dimensional OctreoScan111 SPECT of abdominal manifestation of neuroendocrine tumours. Acta Oncol (Madr) 1993;32:171–6.
   PubMed Web of Science ®Google Scholar
• KMKalkner, ETJanson, SNilsson, SCarlsson, KOberg, JEWestlin. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radiology uptake and tumor markers. Cancer Res 1995;55:5801s–4s.
   PubMed Web of Science ®Google Scholar
• ETJanson, JEWestlin, BEriksson, HAhlstrom, SNilsson, KOberg. 111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577–81.
   PubMed Web of Science ®Google Scholar
• HAhlstrom, BEriksson, MBergstrom, PBjurling, BLangstrom, KOberg. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333–7.
   PubMed Web of Science ®Google Scholar
• HOrlefors, ASundin, UGarske, CJuhlin, KOberg, BSkogseid, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–400.
   PubMed Web of Science ®Google Scholar
• BEriksson, MBergstrom, HOrlefors, ASundin, KOberg, BLangstrom. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 2000;44:68–76.
   PubMedGoogle Scholar
• ASundin, BEriksson, MBergstrom, BLangstrom, KOberg, H. PEOrleforsT in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 2004;1014:246–57.
   PubMed Web of Science ®Google Scholar
• BEriksson, HOrlefors, KOberg, ASundin, MBergstrom, BLangstrom. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19:311–24.
   PubMed Web of Science ®Google Scholar
• KOberg. Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012;2:448–58.
   PubMed Web of Science ®Google Scholar
• BSkogseid, KOberg, LBenson, PGLindgren, LELorelius, GLundquist, et al. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. J Clin Endocrinol Metab 1987;64:1233–40.
   PubMed Web of Science ®Google Scholar
• CLarsson, BSkogseid, KOberg, YNakamura, MNordenskjold. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85–7.
   PubMed Web of Science ®Google Scholar
• KOberg, HBostrom, JFahrenkrug, JFDymling, OBShaffalitsky de Muckadell, GLundqvist. Streptozotocin treatment of a pancreatic tumour producing VIP and gastrin associated with Verner-Morrison syndrome. Acta Med Scand 1979;206:223–7.
   PubMed Web of Science ®Google Scholar
• KOberg, GLundqvist, HBoström. The effect of Streptozotocin in the treatment of endocrine pancreatic tumors and carcinoids. In MKAgrewall, editor. Streptozotocin. North Holland: Elsevier; 1982.
   Google Scholar
• KOberg, KFuna, GAlm. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129–33.
   PubMed Web of Science ®Google Scholar
• KFuna, GVAlm, LRonnblom, KOberg. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983;53:716–24.
   PubMed Web of Science ®Google Scholar
• EWilander, ABengtsson, INorheim, KOberg. Interferon-induced nuclear DNA alterations in malignant carcinoid tumors in vivo. J Natl Cancer Inst 1986;76:429–33.
   PubMed Web of Science ®Google Scholar
• BEriksson, KOberg, GAlm, AKarlsson, GLundqvist, AMagnusson, et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Cancer Treat Rep 1987;71:31–7.
   PubMedGoogle Scholar
• PBurman, THTotterman, KOberg, FAKarlsson. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986;63:1086–90.
   PubMed Web of Science ®Google Scholar
• KOberg, AJakobsson, GGustafsson, EWilander, GLundqvist, MStridsberg. WDHA-syndrome due to a VIP and NPY producing ganglioneuroblastoma. Treatment with SMS 201-995, a somatostatin analogue. Scand J Gastroenterol 1986;Vol 21:228–9.
   Web of Science ®Google Scholar
• KOberg, BEriksson, INorheim. Treatment of malignant neuroendocrine gut and pancreatic tumors with the somatostatin analogue SMS 201-995. Proceedings of Concensus Meeting on Somatostatin analogue SMS 201-995, Sandoz. Phoenix, Arizona, USA; 1987. pp 89–92.
   Google Scholar
• BEriksson, KOberg, TAndersson, GLundqvist, LWide, EWilander. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. Scand J Gastroenterol 1988;23:508–12.
   PubMed Web of Science ®Google Scholar
• KOberg, INorheim, ETheodorsson, HAhlman, GLundqvist, LWide. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989;68:796–800.
   PubMed Web of Science ®Google Scholar
• KOberg, GVAlm. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J Interferon Res 1989;9:S45–9.
   PubMedGoogle Scholar
• KOberg, GAlm, AMagnusson, GLundqvist, ETheodorsson, LWide, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989;81:531–5.
   PubMed Web of Science ®Google Scholar
• LERonnblom, GVAlm, KEOberg. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207–10.
   PubMed Web of Science ®Google Scholar
• BEriksson, BSkogseid, GLundqvist, LWide, EWilander, KOberg. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883–90.
   PubMed Web of Science ®Google Scholar
• CMakridis, KOberg, CJuhlin, JRastad, HJohansson, LELorelius, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377–83.
   PubMed Web of Science ®Google Scholar
• DGrander, KOberg, MLLundqvist, ETJanson, BEriksson, SEinhorn. Interferon-induced enhancement of 2’,5’-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 1990;336:337–40.
   PubMed Web of Science ®Google Scholar
• LERonnblom, GVAlm, KEOberg. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178–83.
   PubMed Web of Science ®Google Scholar
• EMTiensuu Janson, HAhlstrom, TAndersson, KEOberg. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647–50.
   PubMed Web of Science ®Google Scholar
• ETJanson, KOberg. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol (Madr) 1993;32:225–9.
   PubMed Web of Science ®Google Scholar
• ETJanson, LHolmberg, MStridsberg, BEriksson, ETheodorsson, EWilander, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–90.
   PubMed Web of Science ®Google Scholar
• BEriksson, ETJanson, NDBax, MMignon, RMorant, POpolon, et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 1996;57:77–80.
   PubMed Web of Science ®Google Scholar
• BEriksson, JRenstrup, HImam, KOberg. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041–4.
   PubMed Web of Science ®Google Scholar
• BKEriksson, EGLarsson, BMSkogseid, AMLofberg, LELorelius, KEOberg. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293–301.
   PubMed Web of Science ®Google Scholar
• MAfargan, ETJanson, GGelerman, RRosenfeld, OZiv, OKarpov, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001;142:477–86.
   PubMed Web of Science ®Google Scholar
• MLFjallskog, DPGranberg, SLWelin, CEriksson, KEOberg, ETJanson, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101–7.
   PubMed Web of Science ®Google Scholar
• ANWymenga, BEriksson, PISalmela, MBJacobsen, EJVan Cutsem, RHFiasse, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111.
   PubMed Web of Science ®Google Scholar
• SVWelin, ETJanson, ASundin, MStridsberg, ELavenius, DGranberg, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107–12.
   PubMed Web of Science ®Google Scholar
• DLBushnellJr, TMO’Dorisio, MSO’Dorisio, YMenda, RJHicks, EVan Cutsem, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652–9.
   PubMed Web of Science ®Google Scholar
• JLeja, HDzojic, EGustafson, KOberg, VGiandomenico, MEssand. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 2007;13:2455–62.
   PubMed Web of Science ®Google Scholar
• JCYao, MHShah, TIto, CLBohas, EMWolin, EVan Cutsem, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
   PubMed Web of Science ®Google Scholar
• MEPavel, JDHainsworth, EBaudin, MPeeters, DHorsch, REWinkler, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
   PubMed Web of Science ®Google Scholar
• SEkeblad, BSkogseid, KDunder, KOberg, BEriksson. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798–803.
   PubMed Web of Science ®Google Scholar
• SWelin, HSorbye, SSebjornsen, SKnappskog, CBusch, KOberg. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617–22.
   PubMed Web of Science ®Google Scholar
• ONorlen, PStalberg, KOberg, JEriksson, JHedberg, OHessman, et al. Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center. World J Surg 2012;36:1419–31.
   PubMed Web of Science ®Google Scholar
• LKKvols, KEOberg, TMO’Dorisio, PMohideen, WWde Herder, RArnold, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;19:657–66.
   PubMed Web of Science ®Google Scholar
• KOberg, UKnigge, DKwekkeboom, APerren. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii124–30.
   PubMed Web of Science ®Google Scholar